scispace - formally typeset
G

Gaomei Zhao

Researcher at Third Military Medical University

Publications -  16
Citations -  344

Gaomei Zhao is an academic researcher from Third Military Medical University. The author has contributed to research in topics: Chemistry & Viral entry. The author has an hindex of 7, co-authored 12 publications receiving 128 citations.

Papers
More filters
Journal ArticleDOI

Platelet-membrane-camouflaged bismuth sulfide nanorods for synergistic radio-photothermal therapy against cancer.

TL;DR: This study demonstrates a versatile bismuth-containing nanoplatform with tumor-targeting, immune escape, and radiosensitizing functionalities using an autologous cell membrane biomimetic concept that may promote the development of radiotherapy enhancers.
Journal ArticleDOI

Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone.

TL;DR: In this article, the authors showed that human cathelicidin LL37 can simultaneously block viral spike 1 (S1) protein with host angiotensin-converting enzyme-2 (ACE2) and cloak ACE2.
Journal ArticleDOI

Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection.

TL;DR: In this paper, membrane nanoparticles (NPs) prepared from ACE2-rich human renal tubular epithelial cells were discovered to have potent capacity to block SARS-CoV-2 infection.
Journal ArticleDOI

Sympathetic stimulation facilitates thrombopoiesis by promoting megakaryocyte adhesion, migration, and proplatelet formation.

TL;DR: It is demonstrated that both continual noise and exhaustive exercise elevate peripheral platelet levels in normal and splenectomized mice, but not in dopamine β-hydroxylase-deficient mice that lack norepinephrine (NE) and epinephrine (EPI), and the role of sympathetic stimulation in the regulation of thrombopoiesis is characterized.
Journal ArticleDOI

Succinylated casein-coated peptide-mesoporous silica nanoparticles as an antibiotic against intestinal bacterial infection.

TL;DR: A peptide-based nanobiotic with efficacy to combat intestinal infection, especially against drug-resistant bacteria is provided and the biocompatible and readily prepared MSN/SCN delivery system may benefit further intestinal antibiotic design and promote the drug transformation of additional enterogenic functional molecules.